期刊文献+

Survivin抑制剂研究进展 被引量:2

Advances in study of Survivin inhibitors
原文传递
导出
摘要 Survivin作为凋亡抑制蛋白家族的一员,在细胞分裂和抑制细胞凋亡中起到关键作用,被认为是抗癌治疗的重要靶点。目前,已经开发的Survivin抑制剂较少,其中大部分化合物是通过间接抑制作用,而不是通过直接影响Survivin而发挥其抑制剂的作用。本文通过对Survivin蛋白的结构、作用机制和Survivin抑制剂的研究进展进行概述,对进一步研究和开发选择性Survivin抑制剂具有重要意义。 Survivin, a member of the inhibitor of apoptosis proteins family, is considered to be an important target of anticancer treatment for its key role in the control of cell division and cell apoptosis. Currently, only a few Survivin inhibitors have been developed, and most of them reduce Survivin level by interacting with other biomolecules instead of directly interacting with Survivin protein. This review summarizes the structure of Survivin protein, the mechanism of action and research progress of Survivin inhibitors, which may has a great significance in the study of selective Survivin inhibitors in the future.
出处 《药学学报》 CAS CSCD 北大核心 2016年第3期347-355,共9页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(21372156) 辽宁省教育厅高等学校优秀人才支持计划资助项目(LR2013017) 沈阳市科技计划资助项目(F13-316-1-47)
关键词 Survivin抑制剂 抗肿瘤 作用机制 研究进展 Survivin inhibitor anti-tumor mechanism of action research progress
  • 相关文献

参考文献1

二级参考文献26

  • 1Vibert E,Ishizawa T.Hepatocellular carcinoma:Western and Eastern surgeons' points of view[J].J Vise Surg,2012,149(5):e302-e306.doi:10.1016/j.jviscsurg.2012.05.OOL.
  • 2Graf D,VallbShmer D,Knoefel WT,et al.Multimodal treat- ment of hepatocellular carcinoma[J].Eur J Intern Med,2014,25(5):430-437.doi:10.1016/j.ejim.2014.03.001.
  • 3Cao H,Phan H,Yang LX.Improved chemotherapy for he- patocellular carcinoma[J].Anticancer Res,2012,32(4):1379-1386.
  • 4Hennessy BT,Smith DL,Ram PT,et al.Exploiting the PI3K/AKT pathway for cancer drug discovery[J].Nat Rev Drug Discov,2005,4(12):988-1004.doi:10.1038/nrdl902.
  • 5Sarbassov DD,Guertin DA,Ali SM,et al.Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science,2005,307(5712):1098-1101.doi:10.1126/sci- ence.1106148.
  • 6Franke TF,Kaplan DR,Cantley LC,et al.Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate[J].Science,1997,275(5300):665-668.
  • 7Toker A,Yoeli-Lerner M.Akt signaling and cancer:sur- viving but not moving on[J].Cancer Res,2006,66(8):3963-3966.doi:10.1158/0008-5472.CAN-06-0743.
  • 8Hou e d e N,Pourquier P.Targeting the genetic altera- tions of the PI3 K-AKT-mTOR pathway:its potential use in the treatment of bladder cancers[J].Pharmacol Ther,2015,145:1-18.doi:10.1016/j.pharmthera.2014.06.004.
  • 9Holz MK,Blenis J.Identification of S6 kinase I as a novel mam- malian target of rapamycin(mTOR)-phosphorylating kinase[J]. J Biol Chem,2005,280(28):26089-26093.doi:10.1074/jbc. M504045200.
  • 10Psyrri A,Arkadopoulos N,Vassilakopoulou M,et al.Path- ways and targets in hepatocellular carcinoma[J].Expert Rev Anticancer Ther,2012,12(10):1347-1357.doi:10.1586/era.12.113.

共引文献12

同被引文献15

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部